The study randomized effluent 1250 patients, with a mean HbA1c of 9.9%, for the treatment of combin

In an article published in the journal Endocrine Practice, researchers report effluent the results of a new study, which suggests that patients with type 2 diabetes and HbA1c values over 7.5 to 9.0%, combined drug therapy: Sitagliptin with Metformin (G'nuet) led to a higher rate of patients with values HbA1c of 6.5% or less, compared with initial treatment with metformin alone, findings that are consistent with the recommendations of the -AACE/ACE.
Background research researchers explain that the diabetes treatment algorithm recommendations from the -AACE/ACE (American effluent Association of Clinical Endocrinologists and American College of Endocrinology) include an integrated treatment approach as initial effluent therapy to achieve a target HbA1c of 6.5% or less in patients with type 2 diabetes, effluent without a good balance of blood sugar levels.
The estimate was based on data from a study that included patients with type 2 diabetes who have not received antiretroviral therapy before, during effluent which a comparison was made between effluent patients in whom metformin monotherapy effluent were against the combined initial treatment dose - fixed sitagliptin with metformin (G'nuet). The objective was to examine the recommendations of the -AACE/ACE achieving HbA1c target these treatment groups.
The study randomized effluent 1250 patients, with a mean HbA1c of 9.9%, for the treatment of combination therapy (50 mg of sitagliptin with metformin 500 mg twice daily), or treatment with metformin (500 mg twice daily) for 18 weeks. dose treatments raised gradually during the four weeks to 50/1000 mg twice daily with 1,000 mg twice daily, respectively.
After 18 weeks, a higher proportion of patients receiving the combination therapy reached effluent HbA1c values of 6.5% or less, and values lower than 7%, compared to patients treated with metformin alone, each of the three categories HbA1c recommended by the -AACE/ACE (6.5-7.5% , 7.5 to 9.0% and above 9.0%). Of patients with HbA1c values above 7.5 to 9.0% of combination therapy began in -48.6% effluent documented HbA1c values of 6.5% or less after 18 weeks, compared with 23.1% of patients who began treatment with metformin monotherapy (p <0.001).
The authors conclude that in patients with type 2 diabetes with HbA1c between 7.5 to 9.0% at the base, more patients reached target values of 6.5% for sitagliptin with metformin combined ball (G'nuet) compared effluent with metformin monotherapy only. These findings are consistent with the recommendations of the -AACE/ACE initial combination therapy in these patients effluent with type 2 diabetes.
Running on WordPress